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ABSTRACT
Background Multiple myeloma (MM) remains an 
incurable disease and oncolytic viruses offer a well- 
tolerated addition to the therapeutic arsenal. Oncolytic 
reovirus has progressed to phase I clinical trials and 
its direct lytic potential has been extensively studied. 
However, to date, the role for reovirus- induced 
immunotherapy against MM, and the impact of the bone 
marrow (BM) niche, have not been reported.
Methods This study used human peripheral blood 
mononuclear cells from healthy donors and in vitro co- 
culture of MM cells and BM stromal cells to recapitulate 
the resistant BM niche. Additionally, the 5TGM1- Kalw/
RijHSD immunocompetent in vivo model was used to 
examine reovirus efficacy and characterize reovirus- 
induced immune responses in the BM and spleen following 
intravenous administration. Collectively, these in vitro and 
in vivo models were used to characterize the development 
of innate and adaptive antimyeloma immunity following 
reovirus treatment.
Results Using the 5TGM1- Kalw/RijHSD 
immunocompetent in vivo model we have demonstrated 
that reovirus reduces both MM tumor burden and 
myeloma- induced bone disease. Furthermore, detailed 
immune characterization revealed that reovirus: (i) 
increased natural killer (NK) cell and CD8+ T cell 
numbers; (ii) activated NK cells and CD8+ T cells and (iii) 
upregulated effector- memory CD8+ T cells. Moreover, 
increased effector- memory CD8+ T cells correlated with 
decreased tumor burden. Next, we explored the potential 
for reovirus- induced immunotherapy using human 
co- culture models to mimic the myeloma- supportive 
BM niche. MM cells co- cultured with BM stromal cells 
displayed resistance to reovirus- induced oncolysis and 
bystander cytokine- killing but remained susceptible to 
killing by reovirus- activated NK cells and MM- specific 
cytotoxic T lymphocytes.
Conclusion These data highlight the importance of 
reovirus- induced immunotherapy for targeting MM cells 
within the BM niche and suggest that combination with 
agents which boost antitumor immune responses should 
be a priority.
BACKGROUND
Multiple myeloma (MM) is a tumor of 
terminally differentiated plasma cells which 
expand in the bone marrow (BM). MM 
results in the onset of myeloma- induced bone 
disease (MBD) due to increased bone resorp-
tion by osteoclasts and loss of osteoblast func-
tion. MBD is one of the many debilitating 
features of MM which results in bone pain 
and frequent fractures.1 The worldwide inci-
dence of MM is ~114 000 cases per year and 
numbers are expected to increase with an 
aging population.2 Currently, MM remains an 
incurable disease in need of novel treatment 
strategies that are safe and well- tolerated.2
The BM microenvironment has a diverse 
cellular composition, including haemato-
poietic stem cells, mesenchymal stem cells, 
BM stromal cells (BMSCs; fibroblasts and 
epithelial cells) and immune cells. Moreover, 
the BM niche provides a range of cytokines, 
chemokines and growth factors which all 
contribute to MM progression and therapy 
resistance.3 4 Oncolytic viruses (OVs) prefer-
entially infect and kill malignant cells, and 
use multiple mechanisms to eradicate tumor 
cells, including engagement of both innate 
and adaptive antitumor immune responses.5 6 
Oncolytic virotherapy has gained increasing 
attention over recent years following the 
Food and Drug Administration approval of 
Talimogene laherparepvec (T- Vec), a modi-
fied herpes simplex virus-1 (HSV-1), which 
encodes granulocyte- macrophage colony- 
stimulating factor (GM- CSF), for the treat-
ment of advanced melanoma. Unfortunately, 
in comparison to solid malignancies, OVs are 
relatively under investigated in the context 
of hematological malignancies (HM) and, as 
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such, their progression to clinical trials has been limited; 
to date, phase I clinical trials in MM have been reported 
for reovirus, measles virus (MV) and vesicular stomatitis 
virus.7
Reovirus is a double- stranded RNA virus that uses 
junctional adhesion molecule A (JAM- A) for viral entry,8 
kills neoplastic cells through both apoptotic and non- 
apoptotic mechanisms9 10 and can use activated RAS 
signaling for replication and oncolysis9; significantly, 
JAM- A is overexpressed in MM11 and mutated Ras is 
associated with MM progression.12 In accordance with 
this, the direct lytic potential of reovirus against MM 
has been reported13 and early phase clinical trials have 
been carried out using reovirus type 3 Dearing strain 
(T3D; pelareorep).14 Pelareorep was well- tolerated in 
patients with MM, and only low- grade adverse effects 
were reported.14 15
Innate and adaptive immunity are important for 
reovirus efficacy and the secretion of type I inter-
feron (IFN) is a key component of the innate immune 
response.16 IFN-α is important for natural killer (NK) cell 
activation in response to reovirus,16 although a range of 
other pro- inflammatory cytokines mediate the recruit-
ment of NK cells and dendritic cells (DC) to the tumor.17 
Reovirus also enhances the ability of DC to present tumor- 
associated antigens (TAA) for priming of tumor- specific 
cytotoxic T lymphocytes (CTLs).18 Harnessing reovirus- 
induced antitumor immunity has the potential to induce 
immunological memory and long- term cancer remission 
in patients with MM.
Unfortunately, despite promising preclinical data, 
single- agent reovirus treatment was ineffective at treating 
relapsed/refractory MM. This dichotomy highlights the 
need for us to better understand reovirus–host interac-
tions, in particular, which reovirus effector mechanisms 
are induced within the BM niche and which have the 
capacity to eradicate MM cells that are supported by the 
tumor microenvironment. Once identified, key effector 
mechanisms can be prioritized for the development 
of effective combination strategies designed to boost 
reovirus efficacy in clinical trials. Therefore, this study 
aimed to characterize the immune response to reovirus in 
a BM niche and identify key effector mechanisms under-
pinning reovirus efficacy.
METHODS
5TGM1 in vivo model
C57BL/KaLw/RijHSD mice were purchased at age 5–10 
weeks from the St James’s Biomedical Services, Univer-
sity of Leeds. Mice were housed in individually ventilated, 
positive pressure ISOcages (five mice per cage). All mice 
were subjected to a regulated daylight cycle, had access 
to water, standard mouse feed and nesting material and 
were pathogen free. All animals were monitored daily 
and any mice exhibiting hind limb paralysis (HLP), or 
other distress, were euthanized by cervical dislocation.
Reovirus therapy experiment
Both female and male mice aged 5–8 weeks were used 
and all groups were randomized based on age and sex. 
Mouse group numbers were ascertained using the power 
calculation formula (2(SD)2×f(α,β)/Δ2). The α (signifi-
cance level) was 0.05, β (power level) was 90% and both 
Δ (least practicable difference between groups) and SD 
were taken from a pilot study to determine reovirus effi-
cacy. This gave rise to the following power calculation 
(2(8.33)2×10.5/152=6.47) and seven mice/group were 
used for all subsequent in vivo experiments.
On day 0, mice were injected with 2×106 bone- homing 
5TGM1 cells (a kind gift from Prof Oyajobi)19 in 100 µL 
phosphate- buffered saline (PBS) via the lateral tail vein. 
On day 7–9, reovirus or control (PBS) treatment was 
initiated with 3 weekly injections (Monday/Wednesday/
Friday) of 2×107 plaque- forming units (PFU)/mL 
reovirus in 100 µL PBS or 100 µL PBS alone, respectively. 
Treatment continued until the development of HLP in 
PBS- treated mice (20–27 days) when all mice were sacri-
ficed and tissues were harvested for assessment of tumor 
burden, bone analysis and immunophenotyping (see 
online supplemental tables S1 and S2 for details of the 
flow cytometry antibodies used).
Assessment of MBD by micro-CT
To assess bone disease, tibiae were analyzed by micro- CT 
(µCT) using a SkyScan 1272 ex vivo µCT scanner at 50 kV 
and 200 µA, using an aluminum filter of 0.5 mm and pixel 
size of 4.3 µm2, as described previously.20 Bone volume 
(BV)/total volume, trabecular number, trabecular thick-
ness, cortical thickness, lesion area and lesion number 
parameters were then assessed as described previously20 
and according to standard guidelines.21
SYBR Green reovirus RT-qPCR
One- step quantitative PCR (qPCR) reactions were 
prepared in triplicate in 96- well MicroAmp Optical Reac-
tion plates (Applied Biosystems) using the Power SYBR 
Green RNA- to- C
T
 1- Step Kit (ThermoFisher Scientific); 
20 µL reaction mixes included: 0.3 µg RNA, 1× Power 
SYBR Green RT- PCR Mix, 1× RT Enzyme Mix, 0.5 µM of 
σ3 forward and reverse primers and RNase- free water. A 
10fold serial dilution of reovirus RNA, isolated from stock 
reovirus, was included for quantification of reovirus RNA. 
Thermal cycling was performed on the QuantStudio 5 
Real- Time PCR System (Applied Biosystems).
Cell culture
NCI- H929, U266B, JIM3 and OPM2 human MM cell lines, 
KG-1 (an acute myeloid leukemia cell line) and HS-5 
(fibroblast- like) and HS-27 (epithelial- like) BMSCs were 
obtained from the American Type Culture Collection and 
cultured in RPMI-1640 (Sigma- Aldrich) supplemented 
with 10% fetal calf serum (FCS; Gibco). All cells were 
routinely tested for mycoplasma and were free from infec-
tion. Isolation of peripheral blood mononuclear cells (PBMC): 
healthy donor blood was obtained from leukocyte 
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apheresis cones supplied by the National Health Service 
Blood and Transplant unit. PBMC were isolated using 
Lymphoprep (Fresenius- Kabi) and seeded at 2×106 cells/
mL in RPMI-1640 supplemented with 10% FCS.
CellTracker staining
A 5 mM stock solution of Cell Tracker Green (CTG) 
CMFDA fluorescent dye (Invitrogen) was prepared in 
dimethyl sulfoxide and a 2.5 µM working dilution was 
prepared in prewarmed serum- free RPMI-1640. Cells 
were stained at 106/mL for 30 min at 37°C and washed 
three times in complete RPMI-1640 before use.
MM and BMSC co-cultures
HS-5 and HS-27 BMSCs cells were allowed to adhere 
overnight and human MM cell lines (NCI- H929, U266B 
and JIM3) were stained with CTG and added to adherent 
BMSCs at a 1:1 ratio in an equal volume of fresh medium. 
Cells were co- cultured for 24 or 48 hours before use 
(online supplemental figure 1).
PBMC-conditioned medium
PBMC were seeded at 2×106 cells/mL and treated with 0.1 
or 1 PFU/cell reovirus, or mock treated with PBS. After 
48 hours incubation, cells were removed by centrifuga-
tion (400× g for 5 min) and the supernatant was sterile 
filtered using a 0.2 µm syringe filter (Millex, Merck Milli-
pore) and stored at −20°C. To inactivate reovirus, condi-
tioned medium (CM) was UV- irradiated using a C-1000 
UV Crosslinker for 2 min (1200 µJ/cm2) in 2 mL aliquots 
in an open 6- well plate (online supplemental figure S2). 
To remove extracellular vesicles, PBMC- CM was filtered 
using Amicon Ultra-15 centrifugal filters. Reovirus T3D 
strain was provided by Oncolytics Biotech Inc.
MTS assay
A total of 5×104 MM cells were seeded in 50 µL/well and 
50 µL CM was added in triplicate (1:1 dilution in fresh 
medium). Plates were incubated for 96 hours before MTS 
reagent (tetrazolium dye, Abcam) was added. The optical 
density was measured at 450 nm using a Multiscan EX 
microplate reader (ThermoFisher Scientific).
Priming of tumor-specific CTLs
Generation of human myeloid-derived DC
CD14+ monocytes were isolated from PBMC using 
magnetic cell sorting (Miltenyi Biotec). CD14+ cells were 
cultured at 8×105/mL in RPMI-1640, 10% FCS, 800 U/
mL GM- CSF (MBL International) and 500 U/mL inter-
leukin-4 (BioLegend) for 5 days to obtain immature DC 
(iDC).
Generation of tumor-specific CTLs
Tumor cells were either left untreated, or treated with 1 
PFU/cell reovirus for 24 hours. Immature DC were loaded 
with tumor cells (±reovirus treatment) at a 3:1 tumor 
cell:DC ratio for 48 hours and tumor- loaded DC were 
cultured with autologous PBMC at a 1:20-1:30 DC:PBMC 
ratio in CTL medium.6 Cells were incubated for 7 days at 
37 ºC and re- stimulated with tumor- loaded iDC (±reovirus 
treatment) for a further 6 days before use.
Peptide pool stimulation of primed CTLs
PepTivator Peptide Pools (Miltenyi Biotec) consisting 
of 15- mer sequences of amino acids with 11 amino acids 
overlap covering the PRAME, Mucin-1 and MAGE- A1 
proteins were used; PepTivator Peptide Pools were stored 
at 30 nmol/mL at −80°C. For TAA stimulation, 2×106 
autologous CD14+ were incubated with appropriate 
peptide pools for 60 min at 37°C at a final concentration 
of 6 nmol/mL. CD14+ cells (±peptide) were then co- cul-
tured with autologous CTLs at a 2:1 ratio and examined 
for intracellular IFN-γ by flow cytometry.
Flow cytometry
All flow cytometry was performed and analyzed using 
a 2- laser Attune Acoustic Focusing Cytometer (Applied 
Biosystems) or a 4- laser CytoFLEX S (Beckman Coulter) 
and analyzed using appropriate software. Antibodies 
details are provided in online supplemental tables S1 
and S2.
LIVE/DEAD assay
Cells were harvested, washed in 1 mL PBS and stained 
with LIVE/DEAD Fixable Yellow Dead Cell Stain (Invit-
rogen; 500 µL diluted 1:1000 in PBS) for 30 min in the 
dark. Samples were washed with PBS and then fixed with 
300 µL 1% paraformaldehyde (PFA) in PBS.
NK cell and CTL CD107 degranulation assays
Effector lymphocytes were incubated alone or with target 
tumor cells at a 2:1 ratio. After 1 hour at 37 ºC, anti- 
CD107a, anti- CD107b and either anti- CD3/CD8 (CTL 
population) or anti- CD3/CD56 (NK cells) were added, 
along with 10 µg/mL brefeldin A (BioLegend). Samples 
were then incubated for a further 4 hours at 37 ºC, washed 
with fluorescence- activated cell sorting (FACS) buffer 
(PBS, 1% FCS and 0.1% sodium azide) and fixed in 1% 
PFA until acquisition.
Intracellular IFN-γ staining
Primed PBMC were co- cultured with tumor targets or 
peptide- loaded CD14+ cells and treated as described for 
the CD107 degranulation assay (above), without the addi-
tion of CD107 antibodies. Following fixation in 1% PFA 
overnight, cells were washed in FACS buffer, permeabi-
lized in 0.3% saponin (Sigma- Aldrich) in FACS buffer for 
15 min (room temperature) and then stained with a fluo-
rescein isothiocyanate- conjugated IFN-γ antibody prior to 
acquisition.
Flow cytometry-based killing assay
Target cells were either stained with CTG immediately 
prior to the assay, or for target cells co- cultured on BMSCs 
for 48 hours CTG staining occurred prior to co- culture 
set up. Target MM cells were harvested by washing with 
PBS+2.5 mM EDTA and co- cultured with effector cells 
(CTLs and NK cells) at a 25:1 effector:target ratio for 
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5 hours at 37°C. Cells were subsequently stained with the 
yellow LIVE/DEAD and fixed in 1% PFA.
51Chromium release assay
Target cells were labeled with 100 µCi 51Cr (Perkin-
Elmer) per 106 cells for 1 hour at 37°C. Effector cells were 
harvested and co- cultured with 51Cr- labeled target cells at 
different effector:target ratios. Spontaneous release was 
established using target cells in medium and maximum 
release was obtained using 1% Triton- X (Sigma- Aldrich). 
For CTL assays, unlabeled K562 and Daudi target cells 
were included to mitigate NK cell and lymphokine- 
activated killer cell activity. Following the 4 hour incuba-
tion, 50 µL of cell- free supernatant was transferred to a 
LumaPlate (PerkinElmer) and the level of 51Cr was then 
measured using a Microbeta2 scintillation counter (Perki-
nElmer). The per cent cell lysis was calculated as below 
(cpm: counts per minute):
 
% lysis = 100 × sample cpm−spontaneous cpmmaximum cpm−spontaneous cpm 
Statistical analysis
Statistical analysis was performed using Graphpad Prism 
V.7.0 (GraphPad Software, La Jolla, California, USA). P 
values were calculated using either Student’s t- test with 
two- tailed distribution or one- way or two- way analysis of 
variance. Results were considered significant if p value was 
<0.05. Pearson’s r was calculated to evaluate correlation.
RESULTS
In vivo efficacy of reovirus
In vivo efficacy of reovirus following intravenous admin-
istration: the stroma- independent 5TGM1 MM subclone, 
established in immunocompetent C57Bl/KaLw/RijHSD 
mice mimics human MM by secreting paraprotein, 
causing hypercalcaemia, and inducing MBD.22 After 
establishment of 5TGM1 tumors (~1 week postinjection), 
mice received reovirus treatment or PBS (intravenous) 
until the development of HLP in PBS control groups 
(figure 1A). Following reovirus treatment, a significant 
reduction in tumor burden in the BM and spleen was 
observed, compared with the PBS control (figure 1B,C). 
Significantly, decreased tumor burden was also associated 
with reduced MBD as demonstrated by the prevention of 
trabecular bone loss, where higher levels of trabecular 
BV, trabecular thickness and trabecular number were 
observed, in accordance with reduced trabecular separa-
tion (figure 1D).
Characterization of immune effector cells following reovirus 
treatment
We established that 5TGM1 cells were susceptible to 
reovirus- direct oncolysis in vitro (online supplemental 
figure S3A). However, the fact that we were unable to 
detect reovirus in the BM of reovirus- treated animals 
by RT- qPCR on termination of the experiment despite 
repeated reovirus administration (online supplemental 
figure S3B), suggested that reovirus may exert its effects 
through immune- mediated mechanisms. To explore 
this, we examined the proportion and activation status 
of NK cells, CD4+ T cells and CD8+ T cells in the BM 
Figure 1 Reduction in tumor burden and prevention of 
myeloma bone disease following intravenous reovirus 
treatment. (A) Schematic in vivo treatment schedule. Mice 
were injected with 2×106 5TGM1 cells intravenously on day 
0. Reovirus (Reo) therapy (2×107 plaque- forming units) or 
phosphate- buffered saline (PBS) was started on day 7–9 and 
continued three times weekly until development of hind limb 
paralysis in PBS mice (day 21–25). Following sacrifice, the 
bone marrow (BM) and spleen were harvested. Tumor burden 
in the BM (B) and spleen (C) after PBS or reovirus treatment 
was determined as the percentage of CD138+ cells (n=26; 
amalgamated results from repeat experiments). (D) Μicro- CT 
images after treatment with PBS (i) or reovirus (ii). Analyses 
of trabecular bone volume (iii), thickness (iv), number (v) and 
separation in tibias (vi) of 5TGM1- bearing mice (3 weeks 
post- tumor cell injection) treated with PBS or reovirus (Reo). 
Asterisk (*) denotes statistical significance and error bars 
indicate SEM. *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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and spleen following systemic reovirus administration. 
Following reovirus treatment, NK cells and CD4+ T cells 
were more prevalent in the BM (figure 2A,B, respectively) 
and the proportion of CD8+ T cells was increased in both 
the BM and spleen (figure 2C). On assessment of CD69 
expression (an early marker of lymphocyte activation) 
on NK cells and CD8+ T cells, increased expression was 
observed in both the BM and spleen 48 and 96 hours 
post- treatment; CD69 expression was reduced to baseline 
1 week postreovirus treatment, with the exception of NK 
cells within the BM (figure 2D).
To provide further characterization, T cells were pheno-
typed to: (i) examine changes in programmed cell death 
protein 1 (PD-1) expression as a further indicator of 
immune activation/control and (ii) quantify the propor-
tion of naïve T cells (CD44−CD62L+; indicating recon-
stitution of the normal BM) and effector T cells (T
EM
, 
CD44+CD62L−; indicating an antitumor and/or antiviral 
T cell response).23 A significant increase in PD-1 expres-
sion on both CD4+ and CD8+ T cells was observed in the 
spleen following reovirus treatment (online supplemental 
figure S3C); enhanced numbers of CD4+ and CD8+ T
EM
 
cells were also observed, concordant with a decrease in 
naïve T cells (figure 2E). Moreover, in reovirus- treated 
mice there was a significant negative correlation between 
the percentage of CD8+ T
EM
 cells in the spleen and the 
percentage of CD138+ tumor cells in the BM (figure 2F; 
p=0.023, Pearson’s r=−0.62), suggesting a potential role 
for adaptive T cell antitumor immunity for the eradi-
cation of MM cells. In support of this, preliminary data 
demonstrated an enhanced proportion of IFN-γ-pro-
ducing and TNF-α-producing CD8+ T cells following in 
vitro stimulation with 5TGM1 cells (figure 2G), suggesting 
that reovirus- treated animals had a greater percentage 
of 5TGM1- specific CD8+ T cells in the BM and spleen 
(96 hours post- treatment initiation).
Overall, these data demonstrate the in vivo efficacy of 
reovirus against MM and associated MBD, and suggest a 
role for reovirus- induced innate and adaptive antitumor 
immunity for its therapeutic efficacy. However, estab-
lishing the importance of each of these mechanisms in 
the context of human disease is essential to inform the 
future development of reovirus therapy.
Modeling the human BM niche in vitro
In accordance with previous literature,11 we confirmed 
that human MM cell lines (H929, U266B and JIM3) 
expressed the reovirus entry receptor JAM- A; however, 
OPM2 cells were JAM- A negative (online supplemental 
figure S4A). Consistent with this, H929, U266B and JIM3 
cell lines were susceptible to the direct lytic effects of 
reovirus, and OPM2 cells were resistant (online supple-
mental figure S4B). Nonetheless, in vivo, neoplastic MM 
cells do not exist in isolation and it is well recognized 
that the addition of BMSCs to hematopoietic neoplastic 
cells can provide a protective niche and induce a drug- 
resistant phenotype.24 Therefore, we co- cultured MM 
cells with BMSCs and examined the expression of the 
anti- apoptotic protein, Mcl-1, which is essential for the 
survival of malignant plasma cells in the bone marrow25; 
as expected, Mcl-1 was upregulated on co- culture with 
both HS-5 and HS-27 BMSCs.26 Next, we evaluated 
whether addition of BMSCs altered the susceptibility of 
MM cells to reovirus- direct oncolysis. Significantly, HS-27 
BMSCs provided protection against reovirus oncolysis in 
H929, U266B and JIM3 MM cell lines, while HS-5 BMSCs 
protected H929 and JIM3 MM cells (figure 3A). Impor-
tantly, changes in reovirus susceptibility were not due to 
altered JAM- A expression as no significant changes in 
JAM- A expression were observed (figure 3B).
Effect of BMSCs on reovirus-induced bystander cytokine 
killing
To date, reovirus- induced bystander cytokine killing 
has not been reported for MM; however, several cyto-
kines have been implicated as a potential treatment, 
including type I and type II IFNs.27 28 Previous literature 
has reported the induction of type I IFN-α following 
reovirus treatment16 and here we have confirmed its 
secretion from healthy donor PBMC in response to 
reovirus treatment (0.1 or 1 PFU/PBMC) (online 
supplemental figure S5A). Moreover, on more detailed 
assessment of reovirus- induced cytokines using multi-
plex bead arrays we observed the induction of a diverse 
range of cytotoxic cytokines, including type II IFN-γ, 
TNF-α and TRAIL (online supplemental figure S5B). 
To examine reovirus- induced bystander cytokine killing, 
PBMC- CM was harvested (±reovirus treatment) and MM 
cells were cultured in PBMC- CM for 96 hours. PBMC- CM 
collected after reovirus treatment displayed cytotoxicity 
against both reovirus- resistant OPM2 cells and reovirus- 
susceptible H929, U266B and JIM3 cells (figure 4A). To 
confirm that the cytotoxicity was mediated by the pres-
ence of cytokines, the PBMC- CM was filtered to remove 
extracellular vesicles, which did not abrogate its cyto-
toxic effect (online supplemental figure S5C). More-
over, following treatment with recombinant cytokines, 
IFN-α (not TNF-α or IFN-γ) was implicated in the killing 
of H929 cells but not U266B cells, suggesting that addi-
tional, as yet undefined, cytokines are involved in medi-
ating the overall cytotoxic effects of PBMC- CM (online 
supplemental figure S5D). Although we have not defined 
the role for individual cytokines in all cell lines, given 
our previous studies in different HM disease models,6 it 
is expected that multiple cytokines will contribute to this 
effect across different MM cell lines.
Interestingly, on examination of bystander cytokine 
killing in the context of BMSCs, some, although incom-
plete, reversal of killing was observed; co- culture with HS-5 
BMSCs protected H929 cells from reovirus- conditioned 
PBMC- CM cytotoxicity and HS-27 BMSCs protected both 
U266B and JIM3 cells (figure 4B). Of note, it is postulated 
that the differential responses observed with JIM3 cells 
shown in figure 4A,B were due to the reduced exposure 
time used in figure 4B (72 hours instead of 96 hours), 
because of the 24 hours preconditioning period on BMSCs 
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Figure 2 In vivo characterization of natural killer (NK) cells and T cells following intravenous reovirus treatment. The percentage 
of CD3−DX5+ NK cells (A), the percentage of CD3+CD4+ T cells (B) and the percentage of CD3+CD8+ T cells (C) in the bone 
marrow (BM) and spleen (n=22 per group) at the time of sacrifice. (D) Fold increase in CD69 expression on CD3-DX5+ NK cells 
and CD3+CD8+ T cells compared with phosphate- buffered saline (PBS)- treated mice. Data were collected 48 hours, 96 hours 
and 1 week after the first reovirus injection (n=3 mice/time point). (E) At sacrifice, the percentage of CD4+- naïve and CD8+- naïve 
T cells (CD44−CD62L+) and effector/memory T cells (T
EM
, CD44+CD62L−) were quantified in the BM and spleen (n=13). Error bars 
indicate SEM and asterisk (*) denotes statistical significance. (F) Correlation of the percentage of CD138+ tumors cells within the 
bone marrow with the percentage of CD8+ T
EM
 in the spleen. Pearson’s r value is shown. (G) Ninety- six hours post- treatment, 
splenocytes (top) and BM cell (bottom) were isolated and co- cultured with 5TGM1 cells ex vivo for 4 hours in the presence 
of brefeldin A. The percentage of IFN-γ+CD8+ and TNF-α+CD8+ T cells were quantified by flow cytometry. *P<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.
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required prior to treatment with PBMC- CM. Nevertheless, 
it is also possible that PBMC- CM induces a cytostatic effect 
in JIM3 cells, which is detected by MTS assays (figure 4A) 
but not seen using the LIVE/DEAD assay (figure 4B). 
Taken together, these results demonstrate that the cyto-
kine milieu induced by reovirus can have a toxic effect on 
MM cells, even when cells are resistant to reovirus oncol-
ysis (ie, OPM2 cells). However, within the BM niche, MM 
cells can be protected from both direct reovirus oncolysis 
and bystander cytokine killing.
Effect of BMSCs on reovirus-mediated NK cell killing
As demonstrated by the data presented so far, the BM 
niche can protect MM cells from direct reovirus oncol-
ysis and cytokine- mediated killing. However, activa-
tion of immune effector cells (specifically, NK cells and 
CD8+ T cells) within the BM of reovirus- treated animals 
(figure 2D) suggests additional effector mechanisms that 
may be capable of overcoming this resistance phenotype. 
In accordance with previous literature,16 NK cells signifi-
cantly upregulated CD69 following reovirus treatment of 
PBMC (data not shown). Moreover, enhanced NK cell 
degranulation against MM cell targets (figure 5A) and 
NK cell- mediated death was observed after reovirus treat-
ment (figure 5B). Overall, the ability of reovirus- activated 
NK cells to kill MM cells was not significantly abrogated 
on co- culture with BMSCs (except for U266B cells at 
lower reovirus doses), and importantly, NK cell- mediated 
killing of reovirus- resistant OPM2 cells was also observed 
(figure 5B). Consistent with these findings, the expression 
of NK cell activatory ligands on MM cells did not change 
following BMSC co- culture (online supplemental figure 
S6). These results demonstrate that reovirus- activated NK 
cells can effectively kill MM cells that may be protected 
from reovirus- direct oncolysis within the BM niche.
Reovirus-induced MM-specific CTLs
Activation of CD8+ T cells in vivo following reovirus 
delivery, and the negative correlation between CD8+ T
EM
 
cells and tumor burden (figure 2), suggested a potential 
role for T cells in reovirus efficacy; therefore, we sought 
to examine this using human CTL priming assays.6 As 
expected, reovirus treatment of human iDC increased 
expression of CD80, CD86 and HLA- DR on DC (online 
supplemental figure S7A),18 demonstrating its potential to 
support priming of adaptive MM- specific CTLs. However, 
to test this, iDC were loaded with reovirus- treated U266B 
cells and cultured with autologous PBMC over the course 
of 3 weeks. Primed CTLs cells were subsequently evalu-
ated for their tumor specificity using relevant U266B MM 
targets or irrelevant KG-1 controls. Figure 6A demon-
strates that CTLs generated in the presence of reovirus 
specifically kill U266B targets, with no enhanced killing 
of irrelevant KG-1 cells; moreover, CTL degranulation 
was only observed against U266B targets, not irrelevant 
KG-1 controls (figure 6B), and was completely abrogated 
Figure 3 Co- culture of multiple myeloma (MM) cells with bone marrow stromal cells (BMSCs) inhibits reovirus- direct oncolysis. 
H929, JIM3 and U266B cells (labeled with Cell Tracker Green (CTG)) were either treated alone, or co- cultured with HS-5 or 
HS-27 BMSCs at a 1:1 ratio for 24 hours. (A) Cells were treated with 10 plaque- forming units/cell reovirus for 72 hours and cell 
death was evaluated using LIVE/DEAD flow cytometry, after gating on CTG+ MM cells. The percentage of viable cells is shown 
and after normalization to the untreated control for each co- culture condition. (B) Junctional adhesion molecule A (JAM- A) 
expression after co- culture on HS-5 or HS-27 BM stromal cells for 24 hours. Asterisk (*) denotes statistical significance and error 
bars indicate SEM for n=3 experiments. *P<0.05, **p<0.01.
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when major histocompatibility complex (MHC) class I was 
blocked (online supplemental figure S7B), confirming 
the importance of MHC class I–CD8 interactions.
To further characterize the CTL response, the produc-
tion of IFN-γ—secreted in large amounts on antigen 
recognition by CD8+ CTLs and Th1 CD4+ T cells29—was 
examined. ELISA assays confirmed abundant secretion 
of IFN-γ in reovirus- primed CTL cultures, suggestive of 
a Th1- skewed immune response (figure 6C).29 Further-
more, assessment of IFN-γ using intracellular flow 
cytometry demonstrated that CD8+ CTLs (primed using 
reovirus- loaded U266B cells) secreted IFN-γ on recogni-
tion of relevant (U266B), but not irrelevant (KG-1) cells 
(figure 6D). Subsequently, CTLs were challenged with 
peptide pools of TAA (PRAME, mucin-1 and MAGE- A1), 
which are commonly expressed in MM,30 and increased 
IFN-γ production was observed in response to PRAME 
and MAGE- A1 peptides (figure 6E). As expected, CTL 
responses were variable between donors, and although 
not significant, IFN-γ production was also induced 
following stimulation with mucin-1 peptides in some 
donors (figure 6E). Having confirmed that reovirus 
Figure 4 Bystander cytokine killing of human multiple myeloma (MM) cells and the effect of bone marrow stromal cells 
(BMSCs). Peripheral blood mononuclear cell- conditioned medium (PBMC- CM) was collected from untreated PBMC (0 plaque- 
forming units (PFU)/PBMC) or after treatment with reovirus (0.1 or 1 PFU/PBMC) for 48 hours and ultraviolet (UV)- irradiated 
to inactivate replication- competent reovirus. (A) H929, JIM3, U266B and OPM2 cells were cultured alone and treated with 
PBMC- CM for 96 hours and cell viability was determined by MTS. (B) H929, JIM3 and U266B (labeled with Cell Tracker Green 
(CTG)) were co- cultured with HS-5 or HS-27 BM stromal cells at a 1:1 ratio for 24 hours and treated with PBMC- CM for a 
further 72 hours. Cell death was evaluated using LIVE/DEAD flow cytometry, after gating on CTG+ MM cells; percentages were 
normalized to the untreated control for each co- culture condition. *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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can prime CTL responses against well- recognized and 
reported TAA, we next explored the ability of CTLs to 
kill MM in the presence of BMSC support. CTL priming 
assays were performed, as above, and the ability of 
reovirus- primed CTLs to kill U266B cells alone, or U266B 
co- cultured with HS-27 BMSCs (which inhibited reovirus 
oncolysis), was evaluated. Encouragingly, there was no 
significant reduction in the killing of U266B target cells 
with prior co- culture on BMSCs (Figure 6F and online 
supplemental figure S7C).
Importantly, MM- specific CTLs could also be gener-
ated using an alternative reovirus- sensitive MM cell line, 
H929 (online supplemental figure S7Di) and, as observed 
for U266B- specific CTLs, H929- generated CTLs had the 
capacity to kill H929 cells cultured with or without BMSCs 
(online supplemental figure S7Dii). Moreover, although 
Figure 5 Reovirus- activated natural killer (NK) cells kill multiple myeloma (MM) cells which are resistant to reovirus- direct 
oncolysis. (A) Peripheral blood mononuclear cell (PBMCs) were treated with 0.1 or 1 plaque- forming units/cell reovirus for 
48 hours and co- cultured with MM target cells at a 2:1 effector:target ratio for 1 hour, followed by a further 4 hours with brefeldin 
A. CD107a/b expression on NK cells within the PBMC population (±reovirus treatment) following co- culture with H929, U266B, 
JIM3 or OPM2 cells is shown. (B) Cell Tracker Green (CTG)+ MM target cells (±co- cultured with HS-5 or HS-27 BMSCs for 
48 hours) were co- cultured with PBMC (±reovirus treatment) at a 25:1 effector:target ratio for 5 hours. The percentage cell death 
of CTG+ MM cells was determined using LIVE/DEAD. Error bars indicate SEM for n=4 independent experiments and asterisk (*) 
denote statistical significance. *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 6 Reovirus treatment of multiple myeloma (MM) cells stimulates the production of MM- specific cytotoxic T 
lymphocytes (CTLs). (A) CTLs were generated by co- culturing peripheral blood mononuclear cells (PBMC) with autologous 
dendritic cell (DC), preloaded with reovirus- sensitive U266B (±1 plaque- forming units (PFU)/cell reovirus). CTLs generated were 
co- cultured with 51Cr- labeled relevant (U266B) and irrelevant (KG-1) target cells and the percentage cell lysis was determined 
after 4 hours using 51Cr assays (n=6). (B) Reovirus- primed CTLs were co- cultured with relevant (U266B) or irrelevant (KG-1) 
target cells at a 2:1 effector:target ratio and CD107a/b expression on CD3+CD8+ CTL was determined (n=7). (C) Interferon 
(IFN)-γ levels in CTL priming cultures was determined by ELISA (n=6). (D) CTLs generated ±reovirus were co- cultured with 
relevant (U266B) or irrelevant (KG-1) target cells at a 2:1 effector:target ratio for 1 hour, followed by a further 4 hours with 
brefeldin A. CTLs were fixed and permeabilized prior to intracellular IFN-γ quantification (n=7). (E) CTLs generated ±reovirus 
were co- cultured with autologous CD14+ cells loaded with PRAME, mucin-1 and MAGE- A1 peptide pools (1 hour at 37°C). 
Cells were co- cultured at a 2:1 effector:target ratio and intracellular IFN-γ was quantified (n=5). (F) CTLs were co- cultured with 
CTG- labeled U266B target cells alone, or CTG- labeled U266B cells precultured on HS-27 stromal cells for 48 hours, at a 25:1 
effector:target ratio. Cell death of CTG+ U266B cells was determined using LIVE/DEAD. Representative flow cytometry plots 
are shown and the percentage of dead cells (orange gate) is indicated in each plot. Left plots: U266B targets alone. Right 
plots: U266B cells precultured with HS-27 stromal cells. (G) CTLs were generated by co- culturing PBMC with autologous DC, 
preloaded with reovirus- resistant OPM2 cells (±1 PFU/cell reovirus). CTLs generated were co- cultured with 51Cr- labeled relevant 
(OPM2) and irrelevant (KG-1) target cells and the percentage cell lysis was determined after 4 hours using 51Cr assays (n=4). 
Asterisk (*) denotes statistical significance and error bars indicate SEM. *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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CTL priming was less efficient when using reovirus- 
resistant OPM2 MM cells (figure 6G), reovirus was also 
capable of generating OPM2- specific CTLs. Taken 
together, these findings demonstrate that reovirus treat-
ment of MM cells can generate MM- specific CTLs capable 
of killing MM cells, even when they reside in a protective 
BM niche.
DISCUSSION
MM remains an incurable malignancy despite a raft of 
new therapeutic agents, thus, novel therapeutic strategies 
are being actively sought. Previous work demonstrated 
that MM cells are susceptible to the direct lytic effects 
of reovirus13 and that reovirus can reduce MM tumor 
burden, in vivo.31 However, building on these observa-
tions, we have shown that reovirus treatment decreases 
both tumor burden and MBD, and that while human 
MM cell lines (except OPM2) are susceptible to reovirus 
direct oncolysis, permissiveness to infection is reduced 
on co- culture with BMSCs. To our knowledge, this is the 
first time that BMSCs have been reported to protect cells 
from direct OV oncolysis. Indeed, co- culture of pancre-
atic cancer cells with cancer- associated fibroblasts (CAF) 
can potentiate viral propagation in both cancer cells and 
CAF.32 The mechanism underpinning reovirus- resistance 
remains unknown, although one possible explanation 
is upregulation of Mcl-126 and subsequent resistance to 
reovirus- induced apoptosis.9 33
A range of immune effects are induced by reovirus,16 18 
therefore, it was possible that immune- mediated mech-
anisms could circumvent stromal- mediated resistance. 
When immune subsets were examined in our murine 
model, reovirus treatment altered the immune profile 
and induced lymphocyte activation. A significant increase 
in T
EM
 following reovirus treatment, and concordant 
decrease in naïve T cells, is characteristic of long- term 
immunological memory following antigen recogni-
tion34 35; moreover, the induction of antitumor immunity 
was further supported by the increase in PD-1 on CD4 
and CD8 T cells, the presence of 5TGM1- specific CD8+ 
cells and the negative correlation of CD8+ T
EM
 cells with 
tumor burden. Interestingly, we were unable to detect 
reovirus in the BM of reovirus- treated animals on sacri-
fice, suggesting that reovirus does not persist in the BM 
after repeated administrations; early reovirus replication/
oncolysis could play a role in the induction of antitumor 
immunity or reovirus may promote antitumor immune 
responses in the absence of oncolysis, a phenomena that 
has been previously reported.36
Here, we demonstrate that reovirus- induced antimy-
eloma activity engages both innate and adaptive arms of 
the immune system encompassing: (1) cytokine- mediated 
bystander killing; (2) NK cell- mediated cellular cytotox-
icity and (3) priming of MM- specific CTLs. Differential 
effects on direct oncolysis and bystander cytokine killing 
were observed on co- culture with HS-5 or HS-27 BMSCs. 
While the reason for this warrant’s further investigation, 
the most likely explanation is the intrinsic properties of 
the BMSCs used; HS-5 cells produce a range of growth 
factors/cytokines to support MM cell survival, while 
HS-27 cells rely on cell- to- cell interactions.37 It is there-
fore possible that the cytokines secreted from HS-5 cells 
could potentiate OV- induced cytokine killing (as seen 
for JIM-3), although this would be dependent on the 
repertoire of growth factor/cytokine receptors avail-
able. Indeed, differential sensitivity of JIM-3 and H929 
MM cells to anti- IGF-1 receptor antibodies has been 
reported—with enhanced sensitivity in JIM-3—demon-
strating the distinct surface phenotypes of different 
MM cell lines.38 Furthermore, data presented in online 
supplemental figure S4A, and in our previously published 
work,6 showed that JIM-3 and U266B cells express higher 
levels of JAM- A and intercellular adhesion molecule-1 
(important for cell adhesion) than other MM cell lines, 
therefore, enhanced cell- to- cell interactions may make 
these cells more amenable to HS-27 BMSC support.
Previously, the ability of activated NK cells to kill MM 
target cells, including reovirus- resistant OPM2 cells, has 
been reported.39 Importantly, we have expanded these 
observations and demonstrated that reovirus- activated 
NK cells can kill MM cells, irrespective of BM stromal 
support. NK cells (and indeed CTLs) kill target cells via 
the release of cytotoxic granules that contain perforin 
and multiple granzymes. Granzyme B (GrB), commonly 
expressed by NK cells and CTLs, uses multiple pathways 
to induce apoptosis,40 therefore modulation of distinct 
pathways by BMSCs may be sufficient to inhibit reovirus 
oncolysis and OV- induced bystander cytokine killing, but 
insufficient to resist the multimodal action of GrB.
Importantly, reovirus- activated NK cells are specific 
for malignant cells and do not degranulate against non- 
malignant hepatocytes41 or other immune cell popula-
tions present in mixed PBMC cultures (data not shown), 
in keeping with the excellent safety profile of reovirus in 
clinical trials.42 Moreover, while the human in vitro system 
used in this study involved allogeneic MM cell lines, we 
have previously confirmed that NK cells can degranulate 
against autologous tumor cells,16 and here we show that 
murine NK cells degranulate against syngeneic 5TGM1 
cell targets (online supplemental figure S3D). Further-
more, cell death within 4 hours is characteristic of NK 
cell- mediated killing on addition of PBMC and we have 
previously validated the role for NK cells in these well- 
defined in vitro assays.41 43 44 Collectively, our data are 
consistent with a therapeutic role for reovirus- activated 
NK cells and is in agreement with previous work using 
alternative cancer models.45 46
Adaptive T cell antitumor immunity is required for the 
generation of long- term immunological memory. There-
fore, the observation that primed CTLs were effective at 
killing MM targets—irrespective of BM stromal support—
is significant, as is the fact that the CTLs generated had 
specificity towards known TAAs. Interestingly, we were 
also able to prime CTLs against reovirus- resistant OPM2 
cells, suggesting that direct oncolysis was not required, 
12 Müller LME, et al. J Immunother Cancer 2021;9:e001803. doi:10.1136/jitc-2020-001803
Open access 
consistent with our previous work using UV- inactivated 
reovirus which primed melanoma- specific CTLs compa-
rable to replication- competent reovirus.36 With regard 
to the priming of OPM2- specific CTLs, both U266B and 
OPM2 express PRAME and MAGE- A1,47 TAA that were 
recognized by U266B primed- CTLs, therefore, OPM2- 
primed CTLs could share specificity towards the same 
myeloma- associated TAA.
CONCLUSIONS
Our data suggest that induction of antitumor immu-
nity by an OV can overcome stromal- mediated tumor 
resistance—a key mechanism by which MM cells escape 
chemotherapeutic control and give rise to relapse. Here, 
we delineate a combination of innate and adaptive mech-
anisms for immune control of the disease; therefore, 
rationale combination approaches to optimize these 
approaches are required. Furthermore, therapeutic inter-
vention should be considered when disease burden is low 
and immune function is relatively preserved (eg, in remis-
sion after autologous stem cell transplant or during main-
tenance therapy) to eliminate low- level residual disease 
protected within the BM niche.
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